BR0112862A - Derivados de imidazol - Google Patents
Derivados de imidazolInfo
- Publication number
- BR0112862A BR0112862A BR0112862-0A BR0112862A BR0112862A BR 0112862 A BR0112862 A BR 0112862A BR 0112862 A BR0112862 A BR 0112862A BR 0112862 A BR0112862 A BR 0112862A
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- compounds
- syndrome
- pharmaceutical compositions
- conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
"DERIVADOS DE IMIDAZOL". A invenção proporciona compostos de fórmula 1 em que R^ 1^, R^ 2^, R^ 3^ e R^ 4^ são conforme acima definidos e os seus sais farmaceuticamente aceitáveis. Os compostos de fórmula 1 são indicados como tendo atividade de inibição de cdk5, cdk2 e GSK-3. As composições farmacêuticas e métodos que compreendem compostos de fórmula 1 para o tratamento e prevenção de doenças e condições que compreendem o crescimento de célula anormal, tais como câncer, e doenças e condições neurodegenerativas e as afetadas por neurotransmissão de dopamina. São também descritas composições farmacêuticas e métodos que compreendem compostos de fórmula (1) para tratamento de fertilidade masculina e motilidade do esperma; diabetes sacarina; tolerância a glicose enfraquecida; sindrome metabólica ou síndrome X; síndrome do ovário policístico; adipogênese e obesidade; miogênese e fragilidade, por exemplo declínio relacionado com a idade no desempenho físico; sarcopenia aguda, por exemplo atrofia muscular e/ou caquexia associada com queimaduras, repouso na cama, imobilização de membro, ou cirurgia torácica maior, abdominal e/ou ortopédica; sepsia; lesão da medula espinal; perda de cabelo, cabelo mais fino e calvície; e imunodeficiência.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22172400P | 2000-07-31 | 2000-07-31 | |
| PCT/IB2001/001335 WO2002010141A1 (en) | 2000-07-31 | 2001-07-25 | Imidazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0112862A true BR0112862A (pt) | 2003-07-01 |
Family
ID=22829075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0112862-0A BR0112862A (pt) | 2000-07-31 | 2001-07-25 | Derivados de imidazol |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1305295A1 (pt) |
| JP (2) | JP4166084B2 (pt) |
| KR (1) | KR20030019644A (pt) |
| CN (1) | CN1444567A (pt) |
| AP (1) | AP2001002232A0 (pt) |
| AR (1) | AR032629A1 (pt) |
| AU (1) | AU2001270944A1 (pt) |
| BG (1) | BG107469A (pt) |
| BR (1) | BR0112862A (pt) |
| CA (1) | CA2418115A1 (pt) |
| CR (1) | CR6861A (pt) |
| CZ (1) | CZ2003225A3 (pt) |
| DO (1) | DOP2001000220A (pt) |
| EA (1) | EA200300097A1 (pt) |
| EC (1) | ECSP034445A (pt) |
| EE (1) | EE200300049A (pt) |
| GT (1) | GT200100147A (pt) |
| HR (1) | HRP20030048A2 (pt) |
| HU (1) | HUP0303069A3 (pt) |
| IL (1) | IL153787A0 (pt) |
| IS (1) | IS6662A (pt) |
| MA (1) | MA26932A1 (pt) |
| MX (1) | MXPA03000939A (pt) |
| NO (1) | NO20030472L (pt) |
| NZ (1) | NZ523272A (pt) |
| OA (1) | OA12345A (pt) |
| PA (1) | PA8523701A1 (pt) |
| PE (1) | PE20020337A1 (pt) |
| PL (1) | PL365134A1 (pt) |
| SK (1) | SK1042003A3 (pt) |
| SV (1) | SV2002000571A (pt) |
| TN (1) | TNSN01114A1 (pt) |
| UY (1) | UY26862A1 (pt) |
| WO (1) | WO2002010141A1 (pt) |
| ZA (1) | ZA200300819B (pt) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| AU2725000A (en) | 1999-01-13 | 2000-08-01 | Bayer Corporation | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| CA2487948A1 (en) | 2002-06-14 | 2003-12-24 | Applied Research Systems Ars Holding N.V. | Azole methylidene cyanide derivatives and their use as protein kinase modulators |
| US7141561B2 (en) | 2002-07-25 | 2006-11-28 | Sanofi-Aventis Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
| DE10233817A1 (de) * | 2002-07-25 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
| JP2007511203A (ja) | 2003-05-20 | 2007-05-10 | バイエル、ファーマシューテイカルズ、コーポレイション | キナーゼ阻害活性を有するジアリール尿素 |
| KR101139557B1 (ko) | 2003-07-23 | 2012-04-30 | 바이엘 파마슈티칼스 코포레이션 | 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아 |
| DE602005007717D1 (de) * | 2004-03-23 | 2008-08-07 | Pfizer Prod Inc | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen |
| CN101010315A (zh) | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
| RU2399614C2 (ru) | 2004-09-21 | 2010-09-20 | Астеллас Фарма Инк. | Аминоспиртовые производные |
| US20080207594A1 (en) | 2005-05-04 | 2008-08-28 | Davelogen Aktiengesellschaft | Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| WO2007034326A2 (en) | 2005-09-22 | 2007-03-29 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| EP1981884B1 (en) | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| RU2009119181A (ru) | 2006-10-21 | 2010-11-27 | Эбботт Гмбх Унд Ко.Кг (De) | Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3 |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| WO2009130317A1 (en) * | 2008-04-24 | 2009-10-29 | Abbott Gmbh & Co. Kg | 1- (7-(hexahydropyrrolo [3, 4-c] pyrrol-2 (1h) -yl) quin0lin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3) |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| JP6329170B2 (ja) | 2012-12-07 | 2018-05-23 | ケモセントリックス，インコーポレイティド | ジアゾールラクタム |
| CN104918921B (zh) * | 2012-12-21 | 2017-09-22 | 凯莫森特里克斯股份有限公司 | 二唑酰胺 |
| WO2015119249A1 (ja) * | 2014-02-07 | 2015-08-13 | 国立大学法人東京医科歯科大学 | 筋形成促進剤、筋萎縮抑制剤、医薬組成物及びｔａｚ活性化剤 |
| EP3662919A1 (en) | 2015-08-31 | 2020-06-10 | Nutramax Laboratories, Inc. | Compositions comprising magnolia, phellodendron, theanine and/or whey protein |
| GB201605126D0 (en) * | 2016-03-24 | 2016-05-11 | Univ Nottingham | Inhibitors and their uses |
| JP7539231B2 (ja) | 2016-04-07 | 2024-08-23 | ケモセントリクス，インコーポレーテッド | Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減 |
| CN110963996B (zh) * | 2017-10-25 | 2022-09-09 | 西南大学 | 含苯乙酮取代基的靛红唑醇类化合物及其制备方法和医药应用 |
| CN112823151B (zh) * | 2018-07-03 | 2024-11-15 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| GB201908424D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
| US10590087B1 (en) | 2019-08-09 | 2020-03-17 | Pfizer Inc. | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
| US11884634B2 (en) | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
| CN112250636A (zh) * | 2020-11-09 | 2021-01-22 | 广西科技大学 | 5-氨基咪唑类化合物及其合成方法 |
| BR112023023223A2 (pt) | 2021-05-07 | 2024-01-30 | Kymera Therapeutics Inc | Degradadores de cdk2 e usos dos mesmos |
| CN118043305A (zh) | 2021-09-01 | 2024-05-14 | 斯普林渥克斯治疗有限公司 | 尼洛加司他的合成 |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| ZA987385B (en) * | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| ZA987383B (en) * | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| US6489344B1 (en) * | 1998-06-19 | 2002-12-03 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| WO2000021550A2 (en) * | 1998-10-13 | 2000-04-20 | President And Fellows Of Harvard College | Methods and compositions for treating neurodegenerative diseases |
| CO5160260A1 (es) * | 1999-02-19 | 2002-05-30 | Lilly Co Eli | Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido |
| EP1106180B1 (en) * | 1999-12-08 | 2003-11-12 | Centre National de la Recherche Scientifique (CNRS) | Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
-
2001
- 2001-07-23 GT GT200100147A patent/GT200100147A/es unknown
- 2001-07-25 WO PCT/IB2001/001335 patent/WO2002010141A1/en not_active Application Discontinuation
- 2001-07-25 KR KR10-2003-7001455A patent/KR20030019644A/ko not_active Application Discontinuation
- 2001-07-25 BR BR0112862-0A patent/BR0112862A/pt not_active IP Right Cessation
- 2001-07-25 HU HU0303069A patent/HUP0303069A3/hu unknown
- 2001-07-25 SK SK104-2003A patent/SK1042003A3/sk not_active Application Discontinuation
- 2001-07-25 EE EEP200300049A patent/EE200300049A/xx unknown
- 2001-07-25 EP EP01949833A patent/EP1305295A1/en not_active Withdrawn
- 2001-07-25 CA CA002418115A patent/CA2418115A1/en not_active Abandoned
- 2001-07-25 CN CN01813397A patent/CN1444567A/zh active Pending
- 2001-07-25 EA EA200300097A patent/EA200300097A1/ru unknown
- 2001-07-25 CZ CZ2003225A patent/CZ2003225A3/cs unknown
- 2001-07-25 MX MXPA03000939A patent/MXPA03000939A/es active IP Right Grant
- 2001-07-25 PL PL01365134A patent/PL365134A1/xx not_active Application Discontinuation
- 2001-07-25 JP JP2002516273A patent/JP4166084B2/ja not_active Expired - Fee Related
- 2001-07-25 PE PE2001000752A patent/PE20020337A1/es not_active Application Discontinuation
- 2001-07-25 OA OA1200300017A patent/OA12345A/en unknown
- 2001-07-25 IL IL15378701A patent/IL153787A0/xx unknown
- 2001-07-25 NZ NZ523272A patent/NZ523272A/en unknown
- 2001-07-25 AU AU2001270944A patent/AU2001270944A1/en not_active Abandoned
- 2001-07-26 AP APAP/P/2001/002232A patent/AP2001002232A0/en unknown
- 2001-07-27 DO DO2001000220A patent/DOP2001000220A/es unknown
- 2001-07-27 SV SV2001000571A patent/SV2002000571A/es not_active Application Discontinuation
- 2001-07-30 UY UY26862A patent/UY26862A1/es not_active Application Discontinuation
- 2001-07-30 TN TNTNSN01114A patent/TNSN01114A1/fr unknown
- 2001-07-30 AR ARP010103637A patent/AR032629A1/es unknown
- 2001-07-31 PA PA20018523701A patent/PA8523701A1/es unknown
-
2002
- 2002-12-18 CR CR6861A patent/CR6861A/es not_active Application Discontinuation
- 2002-12-19 IS IS6662A patent/IS6662A/is unknown
-
2003
- 2003-01-16 BG BG107469A patent/BG107469A/bg unknown
- 2003-01-20 MA MA27004A patent/MA26932A1/fr unknown
- 2003-01-22 EC EC2003004445A patent/ECSP034445A/es unknown
- 2003-01-24 HR HR20030048A patent/HRP20030048A2/hr not_active Application Discontinuation
- 2003-01-29 ZA ZA200300819A patent/ZA200300819B/en unknown
- 2003-01-30 NO NO20030472A patent/NO20030472L/no not_active Application Discontinuation
-
2008
- 2008-05-19 JP JP2008131176A patent/JP2008255123A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0112862A (pt) | Derivados de imidazol | |
| BR0113574A (pt) | Derivados de pirazol e uso dos mesmos como inibidores de proteìna quinase | |
| BR0201691A (pt) | Derivados de tiazol | |
| BRPI0416212A (pt) | derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação | |
| BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
| BR0308816A (pt) | Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas | |
| BR0211665A (pt) | Composto, composição farmacêutica, método para a redução de glicose, método para a prevenção ou para tratamento de doenças, medicamento para a redução de glicose, medicamento para a prevenção ou para o tratamento de doenças, uso do composto, da composição farmacêutica e do medicamento e processo para a preparação do composto | |
| BR0208811A (pt) | Derivados de pirazol para tratamento de hiv | |
| BR0010257A (pt) | Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método para tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kits de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários ou desejados | |
| SK84396A3 (en) | Acetamide derivative and pharmaceutical agent containing its | |
| BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
| BRPI0410050A (pt) | método de tratamento ou de profilaxia de distúrbios psicóticos, distúrbios de prejuìzo intelectual ou doenças ou condições nos quais a modulação do receptor alfa7-nicotìnico é benéfica, composição farmacêutica, método de tratamento ou de profilaxia de doenças, uso de um composto, composto, e, método de preparação de um composto | |
| DK1124841T3 (da) | Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem | |
| PT1157015E (pt) | Utilizacao de sistemas 2-amino-triazole policiclicos para a preparacao de medicamentos para tratamento de perturbacoes lipometabolicas, da obesidade e da diabetes tipo ii | |
| BR0318533A (pt) | azolidinacarbonitrilas e seu uso como inibidores de dpp-iv | |
| HK1049169B (zh) | 取代的4-苄基氨基喹啉、其製備方法、含有這些化合物的藥物及其應用 | |
| BR0309025A (pt) | Agentes antidiabéticos | |
| DE60106246D1 (de) | Malto-oligosaccharide und deren verwendung | |
| PE20030337A1 (es) | Indan-1-onas sustituidas en c2 y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos | |
| BR0008559A (pt) | Aminas tiazol-2-ilideno policìclicas, processos paraa sua preparação e seu emprego comomedicamento | |
| ECSP961806A (es) | Medicamentos en calidad de kappa opiatagonistas para el tratamiento de enfermedades inflamatorias del intestino | |
| NO20062868L (no) | 5-substituerte imidazoler | |
| TH61869A (th) | อนุพันธ์ไพราโซล |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |